

---

# Nicox: 2018 Extraordinary and Ordinary Shareholder Meetings

---

March 28, 2018  
Sophia Antipolis, France

**Nicox SA** (Euronext Paris: FR0013018124, COX), international ophthalmology company, has convened an ordinary and an extraordinary shareholder meeting on **Thursday May 3, 2018 at 2:00 pm CET** in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.

The documents mentioned in articles R.225-73-1 of the French Code de commerce, including a proxy voting form, will be sent to the shareholders upon written request. These documents will also be made available to shareholders at the headquarters and on the Company's website [www.nicox.com](http://www.nicox.com) by April 12, 2018.

Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, will be posted on Nicox's website by April 12, 2018. Shareholders may also contact the Company's Investor Relations team at [communications@nicox.com](mailto:communications@nicox.com) for any question on the voting process.

In the event the quorum is not reached on first call, Nicox will convene a shareholder meeting on a second call on Thursday May 24, 2018 at 2:00 pm CET in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.

## About Nicox

---

Nicox S.A. is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved New Drug Applications, VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIA™ (cetirizine ophthalmic solution) 0.24%, licensed in the U.S. to Eyeavance. In addition, our promising drug-candidate pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a future-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: [www.nicox.com](http://www.nicox.com).

## Analyst coverage

---

Bryan, Garnier & Co	Hugo Solvet	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France



*The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.*

#### Upcoming financial and business conferences

---

April 8-10	HC Wainwright Global Biotechnology Conference	Monaco, Principality of Monaco
April 16-17	SmallCap Event	Paris, France
May 29	Conférence Gilbert Dupont 16 <sup>th</sup> Annual Healthcare	Paris, France
June 27-28	European MidCap Event	Paris, France
October 1-3	Conférence Cantor Global Healthcare	New York, USA

#### Contacts

---

##### Nicox

Corporate Communications Department  
T +33 (0)4 97 24 53 00  
communications@nicox.com

#### Disclaimer

---

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the '*Document de référence, rapport financier annuel et rapport de gestion 2017*' filed with the French Autorité des Marchés Financiers (AMF) on March 19, 2018 which is available on Nicox's website ([www.nicox.com](http://www.nicox.com)).

##### Nicox S.A.

Drakkar 2  
Bât D, 2405 route des Dolines  
CS 10313, Sophia Antipolis  
06560 Valbonne, France  
T +33 (0)4 97 24 53 00  
F +33 (0)4 97 24 53 99